Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to 'Off-the-Shelf' CAR-T Platform
Tessa’s TT11X utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to target relapsed or refractory CD30-positive lymphomas
Exploring indications for solid tumors, expanding the potential for CAR-T
SINGAPORE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the execution of an exclusive agreement with Baylor College of Medicine for worldwide commercial rights to the allogeneic Epstein-Barr virus specific T-cell (EBVST) technology platform developed jointly by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. at Baylor College of Medicine. Tessa is currently advancing a pipeline of products that utilize CD30.CAR-modified EBVSTs, including its lead allogeneic cell therapy, TT11X, which is being co-developed for the treatment of relapsed or refractory CD30-positive lymphomas.
CD30.ALLO Virus specific T-cells (VSTs) are highly specialized T cells that can recognize CD30+ tumors. CD30 Allogeneic VSTs without genetic modification have demonstrated a strong safety profile and efficacy in early trials with minimal risk of Graft vs Host Disease (GVHD). During the development of the allogeneic technology platform, Tessa and Baylor College of Medicine had an exclusive option agreement for commercial rights to the technology.
Clinical data from an ongoing Phase 1 study of TT11X in CD30-positive lymphomas (BESTA) has demonstrated a favorable safety profile and encouraging signs of efficacy with clinical responses observed in seven of nine patients, including a complete disappearance of tumors reported in four patients. TT11X was recently recognized in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022.
“Allogeneic or ‘off-the-shelf’ CAR-T therapies have the potential to change the paradigm of cancer treatment, and we believe the allogeneic EBVST platform develoed at the Center for Cell and Gene Therapy, at Baylor College of Medicine places Tessa at the forefront of a very substantial therapeutic and business opportunity,” said Thomas Willemsen, Tessa’s President and Chief Executive Officer. “Securing exclusive worldwide commercial rights for therapies developed using the EBVST platform is an important value driver for Tessa as we continue to advance TT11X as a potential treatment for CD30-positive lymphomas, while exploring opportunities to extend the technology to other cancer indications, including solid tumors.”
About Tessa Therapeutics
Cautionary Note on Forward Looking Statements
Tessa Therapeutics Investor Contact
Wilson W. Cheung
Tessa Therapeutics Media Contact
Redefining the Future of Work, Part 1: Augmented and Virtual Reality
New Opportunities in Cloud Storage
Conference Boxed Lunches - For Paid Conference Pass Holders, Exhibitors, Sponsors, Speakers, Press